I-New Breakthrough Therapy ye-Idiopathic Pulmonary Fibrosis

A BAMBA MahhalaRelease 3 | eTurboNews | eTN
Isithombe sikaLinda Hohnholz
Ibhalwe ngu Linda Hohnholz

U-Boehringer Ingelheim umemezele namuhla ukuthi i-US Food and Drug Administration (FDA) inikeze i-Breakthrough Therapy Designation encwadini yayo yokwelapha yophenyo, i-BI 1015550, yokwelapha i-idiopathic pulmonary fibrosis (IPF). I-BI 1015550 iyi-inhibitor yomlomo, i-phosphodiesterase 4B (PDE4B) enamandla okubhekana nakho kokubili i-pulmonary fibrosis - isibazi esingahlehliseki sezicubu zamaphaphu esiba nomthelela omubi ekusebenzeni kwamaphaphu - nokuvuvukala okuhambisana nezifo eziqhubekayo ze-fibrosing interstitial lung (ILDs).           

"Ukuthuthuka okusheshayo kwe-BI 1015550 kuyingxenye yegagasi elilandelayo le-Boehringer Ingelheim lokwelapha okungaba khona okusha kwezifo zamaphaphu aphakathi nendawo okuhloswe ngayo ukulondoloza ukusebenza kwamaphaphu nokwenza ngcono izimpilo zeziguli," kusho uThomas Seck, MD, iphini likamongameli omkhulu, Izindaba Zokwelapha Nezokulawula, I-Boehringer Ingelheim Pharmaceuticals, Inc. “I-BI 1015550 imele i-molecule yokuqala ekilasini lama-PDE4B inhibitors afundelwa i-IPF namanye ama-ILD aqhubekayo e-fibrosing. Sakhe phezu kwefa lethu le-pulmonary fibrosis futhi sisebenza ngokuqokwa kwempumelelo kanye nedatha yomtholampilo ngenhloso yokuthi lo muthi wenoveli ongaba khona ungafinyelela iziguli ngokushesha okukhulu. ” 

Mayelana umbhali

Isithombe sikaLinda Hohnholz

Linda Hohnholz

Umhleli omkhulu we eTurboNews ezinze eTN HQ.

Bhalisa
Yazisa ngakho
isivakashi
1 Amazwana
Ukuba
Okudala kakhulu
Okungaphakathi Okuphakelayo
Buka wonke amazwana
1
0
Ungathanda imibono yakho, ngicela uphawule.x
Yabelana ku...